Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2019 Jan 24;66(5):e27621. doi: 10.1002/pbc.27621

TABLE 2.

Therapy courses

Drug Dose Day
Prephase Prednisone 30 mg/m2 1 to 5 Orally in 3 divided doses
Cyclophosphamide 200 mg/m2 1 to 5 1-hour IV infusion
Intrathecal Methotrexate Age-adjusted 1 or 1 and 4¥
Hydrocortisone
Cytarabine
Course A/AA Dexamethasone 10 mg/m2 1 to 5 Orally in 3 divided doses
Ifosfamide/MESNA 400 mg/m2 1 to 5 1-hour IV infusion
Methotrexate 1–3 g/m2 1 10% infused as a push and 90% in 3 hours
Leucovorin 15 mg/m2 (*) 2 First dose starting at 24 hours after the start of the infusion of
methotrexate and continued every 6 hours for 12 doses.
Cytarabine 150 mg/m2 4 and 5 30-minute IV infusion every 12 hours (4 doses).
Etoposide 100 mg/m2 4 and 5 1-hour IV infusion daily (2 doses)
Vincristine(*) 1.5 mg/m2 1 IV push
Intrathecal Methotrexate Age-adjusted 1 or 4 doses weekly ¥
Hydrocortisone
Cytarabine
Course B/BB







Intrathecal
Dexamethasone
Cyclophosphamide
Methotrexate
Leucovorin

Doxorubicin
Vincristine (**)

Methotrexate
Hydrocortisone
Cytarabine
10 mg/m2
200 mg/m2
1–3 g/m2
15 mg/m2 (*)

25 mg/m2
1.5 mg/m2

Age-adjusted
1 to 5
1 to 5
1
2

4 and 5
1

1
Divided into 3 doses, given orally
1-hour IV infusion
10% infused as a push and 90% in 3 hours
First dose starting at 24 hours after the start of the infusion of methotrexate and continued every 6 hours for 12 doses.
1-hour IV infusion
IV push
*

Block AA only

**

Block BB only

¥

Patients with central nervous system involvement